Skip to main content
Bioera logo

Bioera — Investor Relations & Filings

Ticker · BIE ISIN · IT0005516130 LEI · 815600CE609AFE44D992 XMIL Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2021-05-14 Earnings Release
Country IT Italy
Listing XMIL BIE

About Bioera

https://bioera.it/en/

Bioera S.p.A. is a company specializing in the production and distribution of natural and organic products. Its core business involves the development and marketing of a diverse portfolio that includes organic food, traditional food products, natural cosmetics, herbal remedies, and food supplements. The company focuses on providing consumers with products derived from natural sources, catering to the health and wellness market.

Recent filings

Filing Released Lang Actions
Bioera S.p.A. - Riapprovato progetto bilancio di esercizio e consolidato 31.12.2020
Earnings Release Classification · 1% confidence The document is a press release (COMUNICATO STAMPA) from Bioera S.p.A. dated May 14, 2021. The subject (Oggetto) explicitly states: 'Bioera S.p.A. - Riapprovato progetto bilancio di esercizio e consolidato 31.12.2020' (Re-approved draft annual and consolidated financial statements as of 31.12.2020). The text provides key financial highlights (Ricavi, EBITDA, Risultato netto) for both the parent company and the consolidated group for the year ended December 31, 2020. This content strongly indicates the release of annual financial results and related management commentary. Since it contains the key figures and management discussion surrounding the annual financial statements, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial results, or potentially 'Management Reports' (MDA) due to the detailed explanation of trends. However, the core focus is the announcement of the approved annual financial statements, which is a primary function of an Earnings Release, even if it contains more detail than a typical quarterly ER. Given the comprehensive nature of the financial data presented for the full year, it is a strong candidate for an Earnings Release (ER) or potentially an Interim/Annual Report (IR/10-K). Since it is a press release announcing the results, and not the full statutory 10-K filing itself, ER is the most appropriate classification for the initial public announcement of annual figures. The document is substantial (77k chars), suggesting it is more than just a brief announcement, but it is still framed as a press release announcing the approval of the draft statements. FY 2020
2021-05-14 Italian
Bioera S.p.A. - Variazione calendario finanziario: convocazione consiglio di amministrazione per la riapprovazione della Relazione finanziaria 2020
Report Publication Announcement Classification · 1% confidence The document is an official communication (Informazione Regolamentata n. 0771-37-2021) from Bioera S.p.A. dated May 11, 2021. The subject ('Oggetto') is 'Variazione calendario finanziario: convocazione consiglio di amministrazione per la riapprovazione della Relazione finanziaria 2020' (Change in financial calendar: convocation of the board of directors for the re-approval of the 2020 Financial Report). The text explicitly states that the Board of Directors is being convened to re-approve the Annual Financial Report for the year ended December 31, 2020, due to changes in the subsidiary's financial statements. This document is not the Annual Report (10-K) itself, nor is it a standard Earnings Release (ER) or Interim Report (IR). It is an announcement about a future action concerning the finalization and approval of the annual financial statements, which falls under general regulatory announcements or updates related to financial reporting schedules. Since it is a specific announcement regarding the timing/process of a financial report approval rather than the report itself, and it doesn't fit perfectly into other categories like DIV, CAP, or ER, the most appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement, or potentially RPA if it were announcing the publication date, but here it announces the meeting to *re-approve* the report. Given the nature of updating the market on the process surrounding the annual financial statements, RNS is the best fit as a general regulatory disclosure.
2021-05-11 Italian
Bioera S.p.A. - Relazione società di revisione e pubblicazione relazione finanziaria 2020
Audit Report / Information Classification · 1% confidence The document is an official communication from Bioera S.p.A. regarding the release of its 2020 Annual Financial Report ('Relazione finanziaria annuale 2020'). Crucially, the document explicitly contains and discusses the 'Relazione della società di revisione' (Auditor's Report) from RSM S.p.A., which states an inability to express an opinion ('Dichiarazione di impossibilità di esprimere un giudizio') on both the statutory and consolidated financial statements for the year ended December 31, 2020. This document is not the full Annual Report (10-K) itself, but rather the announcement and the core component of the audit findings related to that annual report. Since it focuses specifically on the standalone audit report and its findings (including the disclaimer of opinion), the most appropriate classification is Audit Report / Information (AR). The document also announces the publication of the full annual report, but the primary content provided here is the auditor's opinion, making AR a better fit than RPA or RNS. FY 2020
2021-05-01 Italian
Bioera S.p.A. - Relazione corporate governance e Relazione remunerazione 2020
Governance Information Classification · 1% confidence The document is titled "RELAZIONE SUL GOVERNO SOCIETARIO E GLI ASSETTI PROPRIETARI ai sensi dell'art. 123-bis TUF" (Report on Corporate Governance and Shareholding Structure pursuant to Article 123-bis of the TUF). This specific report type, focusing on corporate governance, ownership structure, capital structure details, and shareholder agreements, directly corresponds to the requirements for a Governance Information report, often mandated by Italian regulations (TUF refers to the Italian Consolidated Financial Act). This aligns perfectly with the definition for Governance Information (CGR). It is not a full Annual Report (10-K), an Audit Report (AR), or an Earnings Release (ER).
2021-05-01 Italian
Bioera S.p.A. - Relazione finanziaria 2020 e relativi allegati
Annual Report Classification · 1% confidence The document is titled 'Bilancio annuale 2020' (Annual Report 2020) for Bioera S.p.A. It contains a detailed 'Relazione degli Amministratori sulla gestione' (Management Report on Operations), consolidated financial statements, and analysis of the company's performance, market position, and financial results for the fiscal year ending December 31, 2020. It is a comprehensive annual financial report, not an announcement or a summary. FY 2020
2021-04-30 Italian
Bioera S.p.A. - Richiesta di conversione Warrant A e azionisti rilevanti
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement from Bioera S.p.A. dated April 30, 2021, detailing the receipt of requests for the conversion of Warrant A into ordinary shares and a notification from a major shareholder (Negma Group Limited) regarding their shareholding falling below the 3% threshold. The subject line explicitly mentions 'Richiesta di conversione Warrant A e azionisti rilevanti' (Request for conversion of Warrant A and relevant shareholders). This activity—issuance of new shares following warrant conversion and changes in significant share ownership—falls directly under the scope of capital structure changes and major shareholding notifications. Since the document details the mechanics of the capital change (issuance of new shares and remaining warrants) and reports a change in a significant shareholder's stake, it strongly aligns with 'Capital/Financing Update' (CAP) due to the share issuance aspect, and 'Major Shareholding Notification' (MRQ) due to the shareholder disclosure. Given that the primary action described is the conversion leading to new share issuance, CAP is a strong candidate. However, the explicit mention of the shareholder crossing the 3% threshold makes MRQ highly relevant. In cases where financing/capital changes are directly tied to shareholder transactions (like warrant conversion leading to new shares and subsequent shareholder reporting), CAP often covers the issuance, while MRQ covers the ownership change. Since the document covers both the issuance of new shares (CAP) and the resulting change in a major shareholder's stake (MRQ), and the issuance is a direct result of the financing agreement, I will prioritize the financing/capital aspect (CAP) as the core event driving the announcement, while acknowledging the MRQ component. If a single best fit is required, CAP covers the issuance of new shares resulting from the warrant exercise. Let's re-evaluate the definitions. CAP is for 'company fundraising, financing activities, or capital structure changes.' This is a capital structure change. MRQ is for 'Notification of changes in significant share ownership levels (crossing thresholds).' This is also explicitly stated. Since the document reports both the issuance of new shares (CAP) and the shareholder crossing a threshold (MRQ), and the document is a formal press release detailing these specific corporate actions, I will select CAP as it describes the primary corporate action (issuance of shares via conversion), which is a financing activity/capital structure change. If the document were purely about the shareholder crossing the threshold without the conversion details, MRQ would be better. Given the dual nature, CAP is slightly broader and encompasses the issuance aspect.
2021-04-30 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.